Stefan Endres

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4647318/publications.pdf

Version: 2024-02-01

81 papers	10,752 citations	101543 36 h-index	69250 77 g-index
85 all docs	85 docs citations	85 times ranked	15643 citing authors

#	Article	IF	Citations
1	Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. Biological Chemistry, 2022, 403, 495-508.	2.5	6
2	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	3.2	9
3	Flow cytometry detection and quantification of CAR T cells into solid tumors. Methods in Cell Biology, 2022, 167, 99-122.	1.1	2
4	FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D. PLoS ONE, 2022, 17, e0262149.	2.5	6
5	Utilizing chemokines in cancer immunotherapy. Trends in Cancer, 2022, 8, 670-682.	7.4	50
6	A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 2021, 35, 2243-2257.	7.2	24
7	Therapeutic Strategies for Targeting IL-1 in Cancer. Cancers, 2021, 13, 477.	3.7	34
8	CAR TÂcell therapy in solid tumors: aÂshort review. Memo - Magazine of European Medical Oncology, 2021, 14, 143-149.	0.5	17
9	Chimeric Antigen Receptorâ€“Modified T Cells and T Cellâ€“Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	2.3	4
10	Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner. Frontiers in Immunology, 2021, 12, 595390.	4.8	16
11	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
12	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Science Advances, 2021, 7, .	10.3	56
13	Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 2021, 21, 481-499.	28.4	318
14	OAS1/RNase L executes RIG-I ligandâ€“dependent tumor cell apoptosis. Science Immunology, 2021, 6, .	11.9	19
15	Challenges in Clinical Trial Design for T Cellâ€Based Cancer Immunotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 47-49.	4.7	9
16	Determinants of response and resistance to CAR T cell therapy. Seminars in Cancer Biology, 2020, 65, 80-90.	9.6	59
17	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia, 2020, 34, 1017-1026.	7.2	33
18	Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19. Journal of Experimental Medicine, 2020, 217, .	8.5	35

#	Article	IF	Citations
19	Constitutive Expression of CCL22 Is Mediated by T Cellâ€“Derived GM-CSF. Journal of Immunology, 2020, 205, 2056-2065.	0.8	12
20	A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosisâ€“Like Hyperinflammation. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3102-3111.	3.8	20
21	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nature Communications, 2020, 11, 3196.	12.8	43
22	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Cancer Immunology, Immunotherapy, 2020, 69, 2101-2112.	4.2	12
23	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clinical Cancer Research, 2019, 25, 5890-5900.	7.0	31
24	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
25	Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology, 2019, 51, 586-592.	0.6	17
26	Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy. Molecular Cancer Therapeutics, 2019, 18, 2343-2356.	4.1	12
27	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	8.6	401
28	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells, 2019, 8, 472.	4.1	122
29	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 2019, 20, 1283.	4.1	296
30	CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. Journal of Experimental Medicine, 2019, 216, 1170-1181.	8.5	145
31	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. Translational Oncology, 2019, 12, 350-360.	3.7	27
32	Teaching an old dog new tricks: next-generation CAR T cells. British Journal of Cancer, 2019, 120, 26-37.	6.4	240
33	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. British Journal of Cancer, 2019, 120, 79-87.	6.4	36
34	Enhancing tumor T cell infiltration to enable cancer immunotherapy. Immunotherapy, 2019, 11, 201-213.	2.0	108
35	Abstract 5024: Treatment with synthetic RIG-I agonist triphosphate RNA leads to local and systemic anti-tumor effects in a mouse melanoma tumor model. , 2019, , .		0
36	Targeting interleukin-22 for cancer therapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2012-2015.	3.3	37

#	Article	IF	Citations
37	Can we use interleukin-1Î² blockade for lung cancer treatment?. Translational Lung Cancer Research, 2018, 7, S160-S164.	2.8	19
38	CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer, 2018, 18, 1278.	2.6	52
39	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. Frontiers in Immunology, 2018, 9, 1955.	4.8	24
40	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Scientific Reports, 2018, 8, 8810.	3.3	13
41	Nlrp3-dependent IL-1Î² inhibits CD103+ dendritic cell differentiation in the gut. JCI Insight, 2018, 3, .	5.0	22
42	Cancer cells induce interleukin-22 production from memory CD4⁺T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12994-12999.	7.1	115
43	Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy. European Oncology and Haematology, 2017, 13, 66.	0.0	8
44	Cancer cell-derived IL-1Î± induces CCL22 and the recruitment of regulatory T cells. OncoImmunology, 2016, 5, e1175794.	4.6	70
45	A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. OncoImmunology, 2016, 5, e1189051.	4.6	22
46	Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery. Nanoscale, 2016, 8, 938-948.	5.6	93
47	C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. OncoImmunology, 2016, 5, e1105428.	4.6	58
48	FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration. Anticancer Research, 2016, 36, 3139-45.	1.1	6
49	Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive Factor. PLoS ONE, 2015, 10, e0142523.	2.5	3
50	Immunotherapy in Tumors. Deutsches Ärzteblatt International, 2015, 112, 809-15.	0.9	31
51	Impact of a New Fusion Receptor on PD-1â€“Mediated Immunosuppression in Adoptive T Cell Therapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	96
52	Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression. Cancer Research, 2015, 75, 4483-4493.	0.9	59
53	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. Journal of the National Cancer Institute, 2015, 107, 364.	6.3	34
54	Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers. PLoS ONE, 2014, 9, e111757.	2.5	32

#	Article	IF	Citations
55	Selfâ€priming determines high type I <scp>IFN</scp> production by plasmacytoid dendritic cells. European Journal of Immunology, 2014, 44, 807-818.	2.9	63
56	Therapeutic Efficacy of Bifunctional siRNA Combining TGF-Î²1 Silencing with RIG-I Activation in Pancreatic Cancer. Cancer Research, 2013, 73, 1709-1720.	0.9	130
57	Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells. Journal of Thoracic Oncology, 2013, 8, 1032-1042.	1.1	62
58	In breast cancer, a high ratio of tumourâ€infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. Histopathology, 2011, 59, 965-974.	2.9	19
59	An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. International Journal of Cancer, 2011, 128, 897-907.	5.1	72
60	Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance. Cancer Research, 2011, 71, 5123-5133.	0.9	73
61	CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. Clinical Cancer Research, 2011, 17, 1765-1775.	7.0	218
62	Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response. Journal of Immunotherapy, 2010, 33, 935-944.	2.4	26
63	Immunostimulatory RNA Blocks Suppression by Regulatory T Cells. Journal of Immunology, 2010, 184, 939-946.	0.8	55
64	Efficient Eradication of Subcutaneous but Not of Autochthonous Gastric Tumors by Adoptive T Cell Transfer in an SV40 T Antigen Mouse Model. Journal of Immunology, 2010, 185, 2580-2588.	0.8	23
65	Superior Protective Immunity against Murine Listeriosis by Combined Vaccination with CpG DNA and RecombinantSalmonella entericaSerovar Typhimurium. Infection and Immunity, 2009, 77, 5501-5508.	2.2	11
66	5â€²-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12067-12072.	7.1	348
67	Activation of Melanoma Differentiation-Associated Gene 5 Causes Rapid Involution of the Thymus. Journal of Immunology, 2009, 182, 6044-6050.	0.8	34
68	Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunology, Immunotherapy, 2009, 58, 901-913.	4.2	15
69	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonâ€“independent apoptosis in human melanoma cells. Journal of Clinical Investigation, 2009, 119, 2399-411.	8.2	322
70	5â€²-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353
71	Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood, 2007, 109, 2953-2960.	1.4	54
72	5'-Triphosphate RNA Is the Ligand for RIG-I. Science, 2006, 314, 994-997.	12.6	2,094

#	Article	IF	Citations
73	Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model. Journal of Immunology, 2002, 169, 3892-3899.	0.8	178
74	Quantitative Expression of Toll-Like Receptor 1â€“10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. Journal of Immunology, 2002, 168, 4531-4537.	0.8	1,780
75	Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. European Journal of Immunology, 2002, 32, 3235-3245.	2.9	107
76	Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotides. Journal of Molecular Medicine, 2001, 79, 306-313.	3.9	30
77	Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. European Journal of Immunology, 2001, 31, 3026-3037.	2.9	704
78	Identification of CpG oligonucleotide sequences with high induction of IFN-Î±/Î² in plasmacytoid dendritic cells. European Journal of Immunology, 2001, 31, 2154-2163.	2.9	790
79	Distinct CpG oligonucleotide sequences activate human Î³ Î´ T cells via interferon-Î±/-Î². European Journal of Immunology, 2001, 31, 3525-3534.	2.9	68
80	Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, 31, 3026.		3
81	Identification of CpG oligonucleotide sequences with high induction of IFN-Î±/Î² in plasmacytoid dendritic cells. , 2001, 31, 2154.		3